1. Homepagina
  2. Aandelen
  3. Zweden
  4. Nasdaq Stockholm
  5. Implantica AG
  6. Nieuws
  7. Andere talen
    IMP A SDB   SE0014855029

IMPLANTICA AG

(IMP A SDB)
  Rapport
Vertraagde tijd Nasdaq Stockholm  -  23/05 17:29:30 CEST
51.90 SEK   -2.99%
11/05Implantica AG maakt winstcijfers bekend voor het eerste kwartaal eindigend op 31 maart 2022
CI
07/03Implantica Ag kondigt de lancering aan van Refluxstop™ in Oekraïne
CI
21/02Implantica AG kondigt de indiening aan van uitgebreide eHealth-octrooiaanvragen voor zijn platformtechnologie
CI
OverzichtKoersenGrafiekenNieuwsRatingsAgendaOndernemingFinanciŽnConsensusHerzieningenBeursproducten 
OverzichtAl het nieuwsAndere talenPersberichtenOfficiŽle publicatiesSectornieuws
Nieuws in andere talen op IMPLANTICA AG
11/05Implantica AG Reports Earnings Results for the First Quarter Ended March 31, 2022
07/03Implantica Ag Announces Launch of Refluxstop™ in Uk
21/02Implantica AG Announces Filing of Comprehensive eHealth Patent Applications for Its Pla..
18/02Implantica AG Reports Earnings Results for the Fourth Quarter Ended December 31, 2021
18/02Implantica AG Reports Earnings Results for the Full Year Ended December 31, 2021
01/02Implantica Appoints New COO
01/02Implantica AG Appoints Paul Meadas as Chief Operating Officer
2021Implantica Successfully Performs Cadaver Implantations of Pipeline Products and Several..
2021Implantica AG Reports Earnings Results for the Third Quarter and Nine Months Ended Sept..
2021Implantica Names New Chief Market Access, Strategy Officer
2021Implantica AG Appoints Amit Kukreja in the Position of Chief Market Access & Strategy O..
2021Implantica AG Announces Feedback from Its Third Pre-Submission Meeting with the U.S. Fo..
2021Implantica Announces Initial UK Surgical Training for RefluxStopô
2021Certain Class A Shares of Implantica AG are subject to a Lock-Up Agreement Ending on 17..
2021Certain Class B Shares of Implantica AG are subject to a Lock-Up Agreement Ending on 17..
2021Implantica Reports Earnings Results for the First Six Months Ended June 2021
2021Implantica AG Announces Executive Appointments
2021Implantica AG Announces Board Changes
2021Implantica AG Announces Another Prominent Anti-Reflux Center Starts Operating with Impl..
2021Implantica Achieves Regulatory Authorisation for RefluxStopô in New Zealand
2021Implantica AG Reports Earnings Results for the First Quarter Ended March 31, 2021
2021Implantica to Seek Acquisitions
2021Implantica AG announced that it expects to receive SEK 598.78 million in funding from D..
2021Implantica AG Makes Headway in Italy and Spain with Its Medical Device RefluxStopô
2021Implantica Advances in Sweden with its Medical Device Refluxstopô
2021Implantica Ag Announces Earnings Results for the Fourth Quarter and Full Year Ended Dec..
2021Implantica AG's RefluxStopô Makes Strides in the UK
2020Implantica Ag Announces Earnings Results for the Third Quarter and Nine Months Ended Se..
2020Implantica Ag Files Pre-Submission with FDA for RefluxStop
2020Implantica AG has completed an IPO in the amount of SEK 1.1 billion.
2020Implantica AG has filed an IPO in the amount of SEK 1.1 billion.
Volgende evenement op IMPLANTICA AG